Compare ADMA Biologics Inc (ADMA) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs First Trust Cloud Computing ETF — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while First Trust Cloud Computing ETF trades at $138.2. The key difference: First Trust Cloud Computing ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | SKYY | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | — |
52-Week High | $20.38 | $155.17 |
52-Week Low | $7.60 | $104.16 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
SKYY, the First Trust Cloud Computing ETF, trades at $139.01, up 3.08% today, with a bullish technical signal from moving averages but mixed oscillators. The ETF provides diversified exposure to the cloud computing sector, which is benefiting from enterprise digital transformation and AI adoption. Recent news highlights strong inflows into technology ETFs and the launch of AI tools to aid investment decisions.
The outlook for SKYY is positive, driven by sustained demand for cloud services and AI integration, though risks include sector volatility and competitive pressures. Investors should monitor earnings growth of underlying holdings and broader tech sector trends for continued upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
